192 related articles for article (PubMed ID: 19556822)
1. Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Ustaalioglu BB; Bilici A; Seker M; Salman T; Gumus M; Barisik NO; Salepci T; Yaylaci M
Onkologie; 2009 Jul; 32(7):424-6. PubMed ID: 19556822
[TBL] [Abstract][Full Text] [Related]
2. Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Toyoshima M; Iwahashi H; Shima T; Hayasaka A; Kudo T; Makino H; Igeta S; Matsuura R; Ishigaki N; Akagi K; Sakurada J; Suzuki H; Yoshinaga K
J Med Case Rep; 2015 Feb; 9():47. PubMed ID: 25881005
[TBL] [Abstract][Full Text] [Related]
3. Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Erkanli S; Kayaselcuk F; Kuscu E; Bolat F; Sakalli H; Haberal A
Breast; 2006 Aug; 15(4):558-61. PubMed ID: 16311034
[TBL] [Abstract][Full Text] [Related]
4. Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Işçi H; Güdücü N; Basgul AY; Aydinli K; Calay Z; Dünder I
Eur J Gynaecol Oncol; 2011; 32(5):560-2. PubMed ID: 22053676
[TBL] [Abstract][Full Text] [Related]
5. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Karagöz B; Ayata A; Bilgi O; Uzun G; Unal M; Kandemir EG; Ozgün A; Türken O
Onkologie; 2009 Jul; 32(7):421-3. PubMed ID: 19556821
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
7. Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy.
Komeda S; Furukawa N; Kasai T; Washida A; Kobayashi H
J Obstet Gynaecol; 2013 Jan; 33(1):99-101. PubMed ID: 23259900
[No Abstract] [Full Text] [Related]
8. Anastrozole-induced hepatotoxicity.
Zapata E; Zubiaurre L; Bujanda L; Piérola A
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
10. Uterine metastases from breast cancer in a patient under tamoxifen therapy. Case report.
Dessole S; Cherchi PL; Ruiu GA; Meloni GB; Cossu Rocca P
Eur J Gynaecol Oncol; 1999; 20(5-6):416-7. PubMed ID: 10609509
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Bock VL; Friedlander M; Waring D; Kossard S; Wood GK
Australas J Dermatol; 2014 Nov; 55(4):282-5. PubMed ID: 24575835
[TBL] [Abstract][Full Text] [Related]
12. [Uterine metastasis of invasive lobular breast carcinoma. Case report and review of the literature with reference to differential diagnostic problems and clinical consequences].
Kemp B; Schröder W; Hermann A; Biesterfeld S; Rath W
Zentralbl Gynakol; 1997; 119(10):500-2. PubMed ID: 9432828
[TBL] [Abstract][Full Text] [Related]
13. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
14. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
15. [Uterine and ovarian metastases 28 years after the discovery of breast cancer].
Mohseni H; Truong P; Hadjseyd M; Grimonpont A; Dieny A; Mechin-Cretinon I; Chabert P
Presse Med; 2003 Jan; 32(2):67-9. PubMed ID: 12653028
[TBL] [Abstract][Full Text] [Related]
16. Evolving uses of hormonal agents for breast cancer therapy.
Cummings FJ
Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
[TBL] [Abstract][Full Text] [Related]
17. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Lavrenkov K; Man S; Geffen DB; Cohen Y
Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
[TBL] [Abstract][Full Text] [Related]
18. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
19. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
20. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Bell R; Lewis J
Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
